Skip to main content
padlock icon - secure page this page is secure

Recent Patents on Oxidative Stress-Related Biomarkers in Chronic Heart Failure: The Central Role of Endothelium and Myeloperoxidase

Buy Article:

$68.00 + tax (Refund Policy)

Endothelial cells are key modulators of multiple physiological processes, and their impairment may result in the generation of endothelial dysfunction and ultimately cardiovascular diseases. Under physiologic conditions, reactive oxygen and nitrogen mediators of endothelial cells act to propagate signals driven by different stimuli, by forming molecules with a longer half-life like hydrogen peroxide. Reactive oxygen species (ROS) are constantly produced as a consequence of aerobic metabolism. Under physiologic conditions, their tendency to cause oxidative damage is counterbalanced by the action of antioxidants or oxidant-scavenging enzymes. An imbalance in favour of oxidants leads to oxidative stress, which can result in cardiomyocyte apoptosis and reduced bioavailability of vascular nitric oxide (NO). Together, these processes may lead to altered vasodilatation of the coronary, pulmonary and peripheral vascular beds. Myeloperoxidase is a key enzyme, capable of impairing intracellular NO reservoirs as well as producing oxidized amino acids such as 3-chlorotyrosine or 3-nitrotyrosine. Recent literature data have shown that apart neutrophils, this enzyme may be expressed by other cell types, and remarkably by endothelial cells both in vitro and in vivo, as a consequence of the exposure to oxidative stress. In this review we analyze recent literature and patents related to the detection, quantification and role of myeloperoxidase as a biomarker in patients affected by chronic heart failure or other cardiovascular diseases. A particular focus is given to analytical approaches aimed to detect early signals of variations in ROS or related enzymes or their by-products, via serological or other low-invasivity assays. The developments in this field may constitute a key improvement of the ability to manage and treat patients suffering from CHF as well as allowing to elucidate the molecular mechanisms behind the clinical phenomena.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Chronic heart failure; coronary artery disease; diagnostic markers; endothelial dysfunction; endothelium; myeloperoxidase; oxidative stress; prognostic biomarkers; serum assays

Document Type: Research Article

Publication date: September 1, 2013

More about this publication?
  • Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more